Right Drug Dose Now Act

Summary

Right Drug Dose Now Act This bill sets out requirements and activities to address adverse drug events, including using pharmacogenomic testing to prevent them. (Pharmacogenomic testing uses a patient's genetic information to help determine the safety, efficacy, and dosage of medications for treatments.) Specifically, the Department of Health and Human Services (HHS) must report to Congress about the implementation of a national plan to prevent adverse drug events. Additionally, HHS must coordinate with relevant federal agencies on the report and convene a steering committee to update the plan. HHS must also (1) require, as a condition of certification, that health information technologies automatically indicate when pharmacogenomic testing is appropriate before a medication order is completed; and (2) assess electronic health records to identify improvements necessary for developing the capacity for collecting real-world evidence in pharmacogenomics. Furthermore, HHS must consult with the Food and Drug Administration (FDA) to carry out a program to improve reporting of adverse drug events and their association with a patient's genetic status. In addition, the FDA must issue regulations and make other administrative changes to update adverse drug event reporting processes, including to facilitate the acceptance of information directly from electronic health records. The bill also requires the National Human Genomics Research Institute, which is part of the National Institutes of Health, to (1) carry out a public awareness campaign on adverse drug events, and (2) establish a program to educate health care providers and related professionals about pharmacogenomic testing and associated issues.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 28 February 2022

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

2. 28 February 2022

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

3. 28 February 2022

   Introduced

   Introduced in House

   Source: IntroReferral

4. 28 February 2022

   Introduced

   Introduced in House

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 28 February 2022 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 28 February 2022

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 28 February 2022

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 28 February 2022

  Open at official source

Sponsors

• Eric Swalwell · D · Sponsor
• Tom Emmer · R · Sponsor
• Rep. Ross, Deborah K. [D-NC-2] · D · Cosponsor
• · hsif00 · Standing

Related records

No cross-record relationships stored yet.